What Happened

Vaxart, Inc. announced a contract modification with BARDA, releasing $345M in funding to support its Phase 2b COVID-19 oral pill vaccine trial. The modification allows for deeper data analysis and reporting of 12-month results from the Sentinel Cohort and main cohort by 2027.

Who Is Affected

Biotech companies, vaccine developers, and healthcare stakeholders focused on innovative COVID-19 solutions are directly impacted. Vaxart's progress also affects investors and partners in the biotech and pharmaceutical sectors.

Market Impact

• Advances oral vaccine technology, potentially disrupting traditional injectable vaccine markets.
• Creates opportunities for partnerships and collaborations in biotech and healthcare.
• Positions Vaxart as a key player in next-generation COVID-19 vaccine development.

What to Watch

Monitor Vaxart's upcoming 12-month data release from the Sentinel Cohort and the full cohort results in 2027. Additionally, track BARDA's continued support and potential further funding modifications.